ArticleFrontiers in oncology2022
The burden of cervical cancer in China.
Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Chemoradiotherapy With or Without Simultaneous Integrated Boost for Cervical Cancer With Full-Thickness Stromal Invasion: A Phase 3 Randomized Clinical Trial.JAMA network open · 2025Trial
- Factors affecting caregivers' HPV vaccination decisions for adolescent girls: A secondary analysis of a Chinese RCT.PloS one · 2025Trial
- Experiences with HPV self-sampling in India: advancing cervical cancer prevention and screening.BMC public health · 2026Article
- Enhanced diagnostic accuracy of high-grade cervical intraepithelial neoplasia in postmenopausal women through PAX1/JAM3 methylation analysis.International journal of cancer · 2026Article
- Factors influencing Chongqing nurses' HPV vaccination: a cross-sectional survey based on the 5C model.Frontiers in public health · 2026Article
- Assessing the influence of male vaccination on cervical cancer elimination in China under different vaccination coverage scenarios: A modeling study.Human vaccines & immunotherapeutics · 2025Review
- miR-21-5p inhibitor enhances the radiosensitivity of human cervical cancer cells via blocking CPEB3-mediated CDK1/cyclin B pathway.Biochemistry and biophysics reports · 2025Article
- Activation of TRIM37 by ATF6 and degradation of ACSL4: inhibiting ferroptosis and propelling cervical cancer progression.Hereditas · 2025Article
- The influence of menopause age on gynecologic cancer risk: a comprehensive analysis using NHANES data.Frontiers in oncology · 2025Article
- Multi-omics profiling reveals the role of 4-ethylbenzoic acid in promoting proliferation and invasion of cervical cancer.Frontiers in medicine · 2025Article
- Awareness regarding human papillomavirus and willingness for vaccination among college students with or without medical background in Guizhou Province.Human vaccines & immunotherapeutics · 2024Article
- Comparative efficacy and safety of Chinese medicine injections as an adjunctive therapy for cervical cancer in Chinese patients: a network meta-analysis.Pharmaceutical biology · 2024Review
- Nationwide Discrete Choice Experiment on Chinese Guardians' Preferences for HPV Vaccination for Mothers and Daughters.Vaccines · 2024Article
- Epidemiology of HPV-associated cancers past, present and future: towards prevention and elimination.Nature reviews. Clinical oncology · 2024Review
- Efficacy Analysis of Neoadjuvant versus Adjuvant Cisplatin-Paclitaxel Regimens for Initial Treatment of FIGO Stages IB3 and IIA2 Cervical Cancer.Medical science monitor : international medical journal of experimental and clinical research · 2023Article
- The awareness and acceptance of HPV vaccines among parents of primary and junior high school students in China: a meta-analysis.Infectious medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Trends in the incidence, disability-adjusted life-years (DALYs), and mortality rate of cervical cancer remain unknown. Methods: The average annual percent changes (AAPCs) and relative risks (RR) in the incidence, DALYs, and mortality rate were determined using a joinpoint regression analysis; the net age, period, and cohort effects on above rates were evaluated. Results: A significant increase in age-standardized incidence (AAPC, 0.9%; 95CI: 0.8, 1.1) but significant decreases in age-standardized DALYs (AAPC, -0.4%; 95%CI: -0.60, -0.20) and the mortality rate (AAPC, -0.4%; 95CI: -0.6, -0.3) were observed. As for age-specific rates, the incidence was higher in younger age groups, and the DALYs and mortality rate were lower in older age groups. The effects of age included a slight but significant increase in the RR with advancing age from 35 to 94 years; the period effect included a significant increase in the incidence over the 2005-2019 periods; and the cohort effect included a substantial increase in the incidence from earlier to later birth cohorts. Conclusions: The incidence of cervical cancer increased from 1990 to 2019, particularly in younger age groups, and the DALYs and mortality rate decreased in the older age groups. Furthermore, the incidence increased with age, period, and cohort.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.